CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic human GHRH analog that selectively and covalently binds to endogenous albumin after subcutaneous administration, thereby extending its half-life and duration of action. Studies in animals (rats, pigs, and dogs) have shown that several days after a single administration of CJC-1295, serum IGF-I levels are still increased. In a recent report, CJC-1295 administered to healthy subjects has been proven to be effective in causing a sustained dose-dependent stimulation of serum GH and IGF-I levels when injected at intervals of 1–2 wk.

(GH)-releasing hormone (GHRH) is a 44-amino acid peptide that stimulates GH secretion and somatotroph cell proliferation in the pituitary gland through its active 1-29 NH2-terminus peptide. Although daily injection of recombinant human GH is presently the only therapeutic option available for patients with GH deficiency (GHD), GHRH may represent a more valid and physiological approach, especially for children with isolated GHD, in whom this condition seems to be related to altered hypothalamic function rather than to impaired GH secretory capacity. However, GHRH has limited therapeutical use in children because of its very short half-life, requiring multiple daily injections or infusion by a pump.

Ipamorelin is a selective GH-Secretagogue and grehlin receptor agonist (grehlin stimulation compares to GHRP-6/MK-677 with less appetite stimulation side effects). Ipamorelin is unique compared to other GH-Secretagogues because it does not release the same volume of cortisol (stress hormone, can be catabolic), acetylcholine (excessive neurotransmission responses), prolactin (reduction in sex-hormone production and increased side effect profile), and aldosterone (secreted by adrenals to regulate salt/potassium and blood pressure).